Praxis · 2010
[Swiss registry for TNF-alpha blockers in children and adolescents with rheumatological diseases].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sauvain M J, Schalm S B, Bérthet G, Bolz D, Cannizzaro E, Hofer M, Kaiser D, Saurenmann R K, Bolt I B
Аннотация
We created a registry to evaluate long term outcome, efficacy and adverse events for children treated wit TNF-alpha inhibitors in Switzerland. 106 patients (68 female/38 male) were included. 61 patients were treated with Etanercept (Enbrel) and 45 with Infliximab (Remicade). Concomitant treatment at baseline included corticosteroids in 26% and Methotrexate in 75% of the patients. Subjective disease activity three months after initiation of TNF-alpha was better in 81%, worse in 4% and stable in 15% of the patients. In total 24 adverse events in 21 patients were reported. Treatment with TNF-alpha inhibitors seems to be safe and effective for children and adolescents with rheumatologic diseases.
Предметные рубрики MeSH
AdolescentAdverse Drug Reaction Reporting SystemsAntibodies, MonoclonalAntirheumatic AgentsArthritis, JuvenileChildDrug InteractionsDrug Therapy, CombinationEtanerceptHumansImmunoglobulin GInfliximabProduct Surveillance, PostmarketingReceptors, Tumor Necrosis FactorRegistriesRheumatic DiseasesSwitzerlandTreatment OutcomeTumor Necrosis Factor-alphaUveitis